AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3438580 — intervention group
Group type: COMPARATOR
Intervention: Usual medical treatment
Number of subjects: 38
Study 2116312 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptazinol (loading dose 50 mg followed by i.v. infusion 0.5 mg.kg‐1.h‐1)
Number of subjects: 30
Study 2116312 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (loading dose 5 mg followed by i.v. infusion 0.05 mg.kg‐1.h‐1)
Number of subjects: 30
Study 2116312 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 30
Study 30716679 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion program based on self-efficacy theory
Number of subjects: 84
Study 30716679 — intervention group
Group type: COMPARATOR
Intervention: Conventional health education
Number of subjects: 84
Study 27686370 — intervention group
Group type: EXPERIMENTAL
Intervention: High ICFI scores (median score 6, IQR=4-7)
Number of subjects: 2092
Study 27686370 — intervention group
Group type: EXPERIMENTAL
Intervention: Low DDS
Number of subjects: 2092
Study 25475658 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic-index and low-glycemic-load desserts (4 portions/week)
Number of subjects: 61
Study 25475658 — intervention group
Group type: COMPARATOR
Intervention: Usual sweet (1 portion/week)
Number of subjects: 61
Study 24247559 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab + capecitabine (maintenance therapy)
Number of subjects: 123
Study 24247559 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab + XELOX (induction therapy until progression)
Number of subjects: 123
Study 20571769 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group (free hip protectors + education sessions)
Number of subjects: 479
Study 20571769 — intervention group
Group type: EXPERIMENTAL
Intervention: No cost group (fitted with free hip protectors)
Number of subjects: 479
Study 20571769 — intervention group
Group type: COMPARATOR
Intervention: Control group (brochure about hip protectors)
Number of subjects: 479
Study 19583070 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexmedetomidine (loading dose of 1 microg/kg over 10 min and maintenance dose of 0.5 microg/kg/hr)
Number of subjects: 48
Study 19583070 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 48
Study 19583070 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexmedetomidine
Number of subjects: 48
Study 17258823 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month lifestyle intervention
Number of subjects: 13
Study 17258823 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 13
Study 12711925 — intervention group
Group type: COMPARATOR
Intervention: Alcohol consumption (exact dosage and duration not specified)
Number of subjects: 0
Study 12711925 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 0
Study 10229979 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional alkaline nasal douche
Number of subjects: 40
Study 10229979 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterile sea water spray
Number of subjects: 40
Study 10229979 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment without douche)
Number of subjects: 40
Study 8763802 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV Overview of Problems Evaluation System (HOPES)
Number of subjects: 106
Study 8763802 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC Quality of Life Questionnaire (EORTC QLQ-C30)
Number of subjects: 106
Study 1679517 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-blockers
Number of subjects: 0
Study 1679517 — intervention group
Group type: EXPERIMENTAL
Intervention: beta1-selective blockers
Number of subjects: 0
Study 1679517 — intervention group
Group type: EXPERIMENTAL
Intervention: nonselective beta-blockers
Number of subjects: 0
Study 7051761 — intervention group
Group type: COMPARATOR
Intervention: Sulfaisodimidine 1 g four times daily (Group I)
Number of subjects: 26
Study 7051761 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfaisodimidine 2 g twice daily (Group II)
Number of subjects: 26
Study 31962176 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraglottic airway devices (SGA)
Number of subjects: 7
Study 31962176 — intervention group
Group type: EXPERIMENTAL
Intervention: Impedance threshold device (ITD)
Number of subjects: 7
Study 31962176 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal tube (ETT)
Number of subjects: 7
Study 30455335 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose control (HbA1c <7.0%)
Number of subjects: 1791
Study 30455335 — intervention group
Group type: COMPARATOR
Intervention: Standard glucose control (HbA1c <8.5%)
Number of subjects: 1791
Study 30455335 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe hypoglycemia
Number of subjects: 1791
Study 30455335 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy after severe hypoglycemia
Number of subjects: 1791
Study 26875447 — intervention group
Group type: COMPARATOR
Intervention: 20% protein diet
Number of subjects: 80
Study 26875447 — intervention group
Group type: COMPARATOR
Intervention: 27% protein diet
Number of subjects: 80
Study 26875447 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% protein diet
Number of subjects: 80
Study 25470529 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional care programme (TCP), a nurse‐led 4‐week programme
Number of subjects: 108
Study 25470529 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional care programme (TCP)
Number of subjects: 108
Study 25470529 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 108
Study 23312435 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance cognitive therapy (MCT)
Number of subjects: 54
Study 23312435 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic alliance and patient characteristics
Number of subjects: 54
Study 23312435 — intervention group
Group type: EXPERIMENTAL
Intervention: Homework compliance
Number of subjects: 54
Study 21261433 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Strategic Family Therapy
Number of subjects: 480
Study 21261433 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 480
Study 19697822 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg kg(‐1) rocuronium (group E)
Number of subjects: 70
Study 19697822 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg kg(‐1) cis‐atracurium (group N)
Number of subjects: 70
Study 19697822 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg kg(‐1) suxamethonium (group P)
Number of subjects: 70
Study 17085458 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (14 weeks)
Number of subjects: 8
Study 17085458 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued endurance training (additional 14 weeks)
Number of subjects: 8
Study 17085458 — intervention group
Group type: EXPERIMENTAL
Intervention: Detraining (14 weeks)
Number of subjects: 8
Study 17085458 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 8
Study 17085458 — intervention group
Group type: EXPERIMENTAL
Intervention: Detraining
Number of subjects: 8
Study 15209772 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Number of subjects: 155
Study 15209772 — intervention group
Group type: COMPARATOR
Intervention: Human insulin
Number of subjects: 155
Study 11110932 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed radiography
Number of subjects: 269
Study 11110932 — intervention group
Group type: COMPARATOR
Intervention: Conventional screen-film radiography
Number of subjects: 269
Study 9361690 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (PZP) 100 mg orally
Number of subjects: 9
Study 9361690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 1315100 — intervention group
Group type: EXPERIMENTAL
Intervention: Incision plus curettage and primary suture under antibiotic (Clindamycin) cover
Number of subjects: 32
Study 1315100 — intervention group
Group type: COMPARATOR
Intervention: Conventional marsupialization
Number of subjects: 32
Study 3883264 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 400 mg administered one hour before and again four and eight hours after abortion
Number of subjects: 100
Study 3883264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 3883264 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole prophylaxis
Number of subjects: 100
Study 3883264 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 100
Study 3883264 — intervention group
Group type: COMPARATOR
Intervention: Placebo (ampicillin/pivampicillin)
Number of subjects: 100
Study 3883264 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole and Placebo
Number of subjects: 100
Study 30629845 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow milk formula
Number of subjects: 0
Study 30629845 — intervention group
Group type: COMPARATOR
Intervention: Extensively hydrolyzed protein formula
Number of subjects: 0
Study 29106076 — intervention group
Group type: EXPERIMENTAL
Intervention: 4F‐PCC (50 IU kg‐1)
Number of subjects: 147
Study 29106076 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA (1.0 g)
Number of subjects: 147
Study 29106076 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 147
Study 27710596 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin (500 mg/day)
Number of subjects: 50
Study 27710596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 25144550 — intervention group
Group type: EXPERIMENTAL
Intervention: IS + EPAP
Number of subjects: 14
Study 25144550 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 14
Study 23321990 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence plus condom use
Number of subjects: 300
Study 23321990 — intervention group
Group type: COMPARATOR
Intervention: Abstinence only
Number of subjects: 300
Study 21205050 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention
Number of subjects: 616
Study 21205050 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 616
Study 18537053 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine
Number of subjects: 49
Study 18537053 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting mean flow velocity
Number of subjects: 49
Study 18537053 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatility index (PI)
Number of subjects: 49
Study 18537053 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine application
Number of subjects: 49
Study 17143986 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment plus usual care
Number of subjects: 409
Study 17143986 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 409
Study 12655281 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ)
Number of subjects: 12
Study 10929922 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg once daily
Number of subjects: 659
Study 10929922 — intervention group
Group type: COMPARATOR
Intervention: Fexofenadine 60 mg twice daily
Number of subjects: 659
Study 10929922 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching to loratadine after initial therapy with fexofenadine
Number of subjects: 659
Study 10929922 — intervention group
Group type: COMPARATOR
Intervention: Switching to fexofenadine after initial therapy with loratadine
Number of subjects: 659
Study 9052131 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmentally appropriate instructional program on germs and handwashing
Number of subjects: 0
Study 9052131 — intervention group
Group type: COMPARATOR
Intervention: Usual handwashing procedures (Control)
Number of subjects: 0
Study 8094826 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 1011
Study 8094826 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass surgery (CABG)
Number of subjects: 1011
Study 8094826 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 1011
Study 8094826 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1011
Study 3535757 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (100 mg three times daily)
Number of subjects: 240
Study 3535757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 29940952 — intervention group
Group type: EXPERIMENTAL
Intervention: Panel of circulating microRNAs combined with exacerbation clinical score
Number of subjects: 153
Study 29940952 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 well-detected circulating microRNAs
Number of subjects: 153
Study 29940952 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-microRNA model (miR-146b, miR-206, miR-720)
Number of subjects: 153
Study 27184170 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 50 mg
Number of subjects: 32
Study 27184170 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg
Number of subjects: 32
Study 27184170 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg
Number of subjects: 32
Study 27184170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 25068344 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous fat injection (group A)
Number of subjects: 49
Study 25068344 — intervention group
Group type: COMPARATOR
Intervention: Autologous fat injection with plasma rich in growth factors (group B)
Number of subjects: 49
Study 25068344 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 49
Study 22926606 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 289
Study 22926606 — intervention group
Group type: COMPARATOR
Intervention: haloperidol
Number of subjects: 289
Study 20621285 — intervention group
Group type: EXPERIMENTAL
Intervention: Implied auditory elements in sentences
Number of subjects: 0
Study 20621285 — intervention group
Group type: COMPARATOR
Intervention: Control task (unrelated sound categorization task)
Number of subjects: 0
Study 18971381 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight supported treadmill training (BWSTT)
Number of subjects: 13
Study 17041232 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted decision support technology
Number of subjects: 1286
Study 17041232 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1286
Study 12975743 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular coiling
Number of subjects: 100
Study 12975743 — intervention group
Group type: COMPARATOR
Intervention: Surgical clipping
Number of subjects: 100
Study 10634841 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% amethocaine gel (Ametop)
Number of subjects: 60
Study 10634841 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 60
Study 8124992 — intervention group
Group type: EXPERIMENTAL
Intervention: Band electrodes
Number of subjects: 21
Study 8124992 — intervention group
Group type: COMPARATOR
Intervention: Spot electrodes
Number of subjects: 21
Study 2671112 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS 201‐995 (50 micrograms)
Number of subjects: 8
Study 793304 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 20
Study 793304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31290018 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Technique (DT)
Number of subjects: 30
Study 31290018 — intervention group
Group type: EXPERIMENTAL
Intervention: Semidirect Technique (SDT)
Number of subjects: 30
Study 31290018 — intervention group
Group type: COMPARATOR
Intervention: Both techniques (DT and SDT)
Number of subjects: 30
Study 30414260 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla‐300)
Number of subjects: 0
Study 30414260 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine 100 U/mL (Gla‐100)
Number of subjects: 0
Study 27979383 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg every 3 weeks
Number of subjects: 1225
Study 27979383 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel 75 mg/m2 every 3 weeks
Number of subjects: 1225
Study 27979383 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab in PD-L1 expression population (TC1/2/3 or IC1/2/3)
Number of subjects: 1225
Study 27979383 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel in PD-L1 expression population (TC1/2/3 or IC1/2/3)
Number of subjects: 1225
Study 27979383 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab in PD-L1 low or undetectable subgroup (TC0 and IC0)
Number of subjects: 1225
Study 27979383 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel in PD-L1 low or undetectable subgroup (TC0 and IC0)
Number of subjects: 1225
Study 27979383 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 1225
Study 27979383 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 1225
Study 26369410 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance-based financing (PBF)
Number of subjects: 5781
Study 26369410 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no PBF)
Number of subjects: 5781
Study 22491891 — intervention group
Group type: EXPERIMENTAL
Intervention: Denicotinized cigarettes
Number of subjects: 22
Study 22491891 — intervention group
Group type: COMPARATOR
Intervention: Average nicotine cigarettes
Number of subjects: 22
Study 20087330 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg) enema treatment once daily for 14 days
Number of subjects: 14
Study 20087330 — intervention group
Group type: COMPARATOR
Intervention: Mesalazine (1 g) enema treatment once daily for 14 days
Number of subjects: 14
Study 18237696 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-bundle (DB) ACL reconstruction
Number of subjects: 70
Study 18237696 — intervention group
Group type: COMPARATOR
Intervention: Single-bundle (SB) ACL reconstruction
Number of subjects: 70
Study 16601218 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of Results (KR)
Number of subjects: 37
Study 16601218 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of Performance (KP)
Number of subjects: 37
Study 16601218 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 37
Study 12745200 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil SR plus trandolapril
Number of subjects: 463
Study 12745200 — intervention group
Group type: COMPARATOR
Intervention: atenolol plus chlorthalidone
Number of subjects: 463
Study 10950038 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancrelipase
Number of subjects: 74
Study 10950038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 9335444 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened persons (faecal occult blood test)
Number of subjects: 206
Study 9335444 — intervention group
Group type: COMPARATOR
Intervention: Not screened (control group)
Number of subjects: 206
Study 8192751 — intervention group
Group type: COMPARATOR
Intervention: Circulating immune complexes
Number of subjects: 221
Study 8192751 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of circulating immune complexes
Number of subjects: 221
Study 8192751 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately or poorly differentiated tumors
Number of subjects: 221
Study 8192751 — intervention group
Group type: EXPERIMENTAL
Intervention: High ratio of immune complex-dissociated to native antibody titer
Number of subjects: 221
Study 8192751 — intervention group
Group type: EXPERIMENTAL
Intervention: Native antibody titers
Number of subjects: 221
Study 8192751 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune complex levels
Number of subjects: 221
Study 2421120 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-cemented prostheses
Number of subjects: 36
Study 2421120 — intervention group
Group type: COMPARATOR
Intervention: Cemented prostheses
Number of subjects: 36
Study 31345627 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (combined groups, every 2 weeks and every 3 weeks)
Number of subjects: 834
Study 31345627 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab
Number of subjects: 834
Study 31345627 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (combined groups)
Number of subjects: 834
Study 29127483 — intervention group
Group type: EXPERIMENTAL
Intervention: High-definition transcranial direct current stimulation (HD-tDCS) of dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 13
Study 29127483 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 13
Study 27855365 — intervention group
Group type: COMPARATOR
Intervention: RFA alone (Group A)
Number of subjects: 60
Study 27855365 — intervention group
Group type: EXPERIMENTAL
Intervention: RFA plus CIK (Group B)
Number of subjects: 60
Study 27855365 — intervention group
Group type: COMPARATOR
Intervention: RFA (in 8 patients with CEA > 50 ng/mL)
Number of subjects: 60
Study 27855365 — intervention group
Group type: EXPERIMENTAL
Intervention: CIK cell therapy (in 8 patients with CEA > 50 ng/mL)
Number of subjects: 60
Study 23727530 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory training
Number of subjects: 0
Study 23727530 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive and yoked training groups
Number of subjects: 0
Study 23727530 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal working memory performance
Number of subjects: 0
Study 22614972 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-calorie weight loss diet
Number of subjects: 439
Study 22614972 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate- to vigorous-intensity aerobic exercise
Number of subjects: 439
Study 22614972 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined reduced-calorie weight loss diet and moderate- to vigorous-intensity aerobic exercise
Number of subjects: 439
Study 22614972 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 439
Study 20485161 — intervention group
Group type: EXPERIMENTAL
Intervention: Darapladib
Number of subjects: 26000
Study 20485161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26000
Study 18949289 — intervention group
Group type: EXPERIMENTAL
Intervention: Propolis orabase gel (PRO)
Number of subjects: 0